A Randomized, Multi-center, Open-label, Active-controlled Phase 3 Trial to Assess the Efficacy and Safety of Octreotide Subcutaneous Depot (CAM2029) Versus Octreotide LAR or Lanreotide ATG in Patients With GEP-NET
The purpose of this study is to compare the effectiveness and safety of CAM2029 to octreotide LAR or lanreotide ATG in patients with advanced, well-differentiated GEP-NET. Patients who experience progressive disease in the randomized part of the study may proceed to an open-label extension part with intensified treatment with CAM2029.
Phase: Phase 3
Sponsor: Camurus AB
Fiona Stanley Hospital (Oncology)
11 Robin Warren Dr, Murdoch WA 6150, Australia
Primary Contact : Caroline Stone, caroline.stone@health.wa.gov.au , (08) 6152 6530
Secondary Contact : Edwin Tan, Edwin.tan@health.wa.gov.au , 61861526720
Read more here.
